Xilio Therapeutics Doses First Participant In Its Phase 1/2 Clinical Study Of XTX501 To Treat Metastatic Non-Small Cell Lung Cancer
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been
Share
Why It Matters
Xilio started testing a new cancer medicine on real patients. When a drug company reaches this stage, watch if patients tolerate it well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.